Ownership
Private
Employees
~50
Stage
Phase 2
Modalities
Protein therapeutics

Venturis Therapeutics General Information

Clinical stage company developing FGF-1 based therapeutics for vascular diseases. Has completed heart trial (referenced in ABC News report).

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

FGF-1
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Venturis Therapeutics's pipeline data

Book a demo

Key Partnerships

Prevail InfoWorks

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Venturis Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Venturis Therapeutics's complete valuation and funding history, request access »

Venturis Therapeutics Investors

Calvin A. Wallen III
Investor Type: Venture Capital
Holding: Minority